reports
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the ...
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the ® CDx Test as the Companion Diagnostic (CDx) for ® (ni...
- Jonathan Moreland
XRAY DENTSPLY SIRONA INC.
WAT WATERS CORPORATION
TGL. TECNOGLASS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
SFBS SERVISFIRST BANCSHARES INC
ROCK GIBRALTAR INDUSTRIES INC.
NSP INSPERITY INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MYGN MYRIAD GENETICS INC.
MLAB MESA LABORATORIES INC.
IP INTERNATIONAL PAPER COMPANY
GOGO GOGO INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
CRG CRH PLC
PLBC PLUMAS BANCORP
BWFG BANKWELL FINANCIAL GROUP
HOG HARLEY-DAVIDSON INC.
MPB MID PENN BANCORP INC.
SSP THE E.W. SCRIPPS COMPANY
SONO SONOS
KOS KOSMOS ENERGY LTD.
AVTR AVANTOR
AHCO INC.
CMTV ADAPTHEALTH
FOUR COMMUNITY BANCORP INC. VT
VERX SHIFT4 PAYMENTS
ADV INC.
EOSE VERTEX
CSU INC.
IMNM ADVANTAGE SOLUTIONS INC (A)
GRNT EOS ENERGY ENTERPRISES INC (A)
ACVA CAPITAL SENIOR LIVING
CPNG IMMUNOME
TKNO GRANIT SKOPKE
QSI ACV AUCTIONS INC.
TCBX COUPANG
BLCO ALPHA TEKNOVA
SMRT INC.
KRRO QUANTUM-SI INC
NCDL THIRD COAST BANCSHARES INC
FG BAUSCH + LOMB CORP
LYEL SMARTRENT INC
KORRO BIO INC
NUVEEN CHURCHILL DIRECT LENDING CORP
F AND G ANNUITIES AND LIFE
INC.
LYELL IMMUNOPHARMA INC.
- Jonathan Moreland
CSGP COSTAR GROUP INC
XRAY DENTSPLY SIRONA INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
NWBI NORTHWEST BANCSHARES INC.
MYGN MYRIAD GENETICS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
WHF WHITEFIELD
ORN ORION GROUP HOLDINGS
THO THOR INDUSTRIES INC.
TTEC TELETECH HOLDINGS
HOG INC.
GO HARLEY-DAVIDSON INC.
ALT GROCERY OUTLET HOLDING
TSLX ALTIMMUNE INC
VERX SIXTH STREET SPECIALTY LENDING
ADV INC.
TKNO VERTEX
AIRS INC.
QSI ADVANTAGE SOLUTIONS INC (A)
FRST ALPHA TEKNOVA
TCBX INC.
EBC AIRSCULPT TECHNOLOGIES INC
NBBK QUANTUM-SI INC
MXF PRIMIS FINANCIAL CORP
LYEL THIRD COAST BANCSHARES INC
EASTERN BANKSHARES INC
NB BANCORP INC.
THE MEXICO FUND
INC.
LYELL IMMUNOPHARMA INC.
Myriad Commercially Launches Precise MRD with Select Community Oncolog...
Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...
- Jonathan Moreland
VNO VORNADO REALTY TRUST
TYL TYLER TECHNOLOGIES INC.
TBI TRUEBLUE INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PODD INSULET CORPORATION
NEU NEWMARKET CORPORATION
MYGN MYRIAD GENETICS INC.
MSCI MSCI INC. CLASS A
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HMN HORACE MANN EDUCATORS CORPORATION
HCI HCI GROUP INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
CEVA CEVA INC.
CAR AVIS BUDGET GROUP INC.
OFIX ORTHOFIX INTERNATIONAL N.V.
WY WEYERHAEUSER COMPANY
TZOO TRAVELZOO
FIVN FIVE9 INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
SXC SUNCOKE ENERGY INC.
WINA WINMARK CORP.
ITIC INVESTORS TITLE CO.
GGT THE GABELLI MULTIMEDIA TRUST
CNDT CONDUENT INC.
HLNE HAMILTON LANE INCORPORATED CLASS A
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
BOTJ BANK OF THE JAMES FINANCIAL GROUP INC.
UBER UBER TECHNOLOGIES INC.
AVTR AVANTOR
VERX INC.
BIGC VERTEX
NBR INC.
SLQT BIGCOMMERCE HOLDINGS
DLHC NABORS INDUSTRIES LTD.
ABCL SELECTQUOTE
CVRX INC.
ELF DALEIGH HOLDINGS CORP
FLYW ABCELLERA BIOLOGICS
BLCO CVRX
FSCO INC.
CADL E.L.F. BEAUTY
CVI INC.
TLSI FLYWIRE CORP
ASST BAUSCH + LOMB CORP
EKSO FS CREDIT OPPORTUNITIES CORP.
LNZA CANDEL THERAPEUTICS
INC.
CVR ENERGY
INC.
TRISALUS LIFE SCIENCES INC
ASSET ENTITIES INC.
EKSO BIONICS HOLDINGS INC.
LANZATECH GLOBAL INC
- Jonathan Moreland
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact ...
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Re...
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, H...
FirstGene Study Demonstrates High Analytical Sensitivity and Specifici...
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the in Clinical Chemistry. The showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene condit...
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial...
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of ...
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study...
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch Precise MRD with select...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Y...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the ...
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Confe...
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET). The presentation will be available through a live webcast and archived at . About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated t...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at ...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS). The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ul...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI ...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), and , today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leader...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcas...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Heredit...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs 100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced —the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). The...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 Nati...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among ...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterat...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Th...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to Ge...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disord...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.